- Home
- PMCB vs SCNX Comparison
PMCB vs SCNX Comparison
Compare PMCB & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMCB | SCNX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 16.2M |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PMCB | SCNX |
|---|---|---|
| Price | $0.41 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 319.4K | ★ 612.4K |
| Earning Date | 09-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,009.57 |
| Revenue Next Year | N/A | $259.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.33 | $0.24 |
| 52 Week High | $1.51 | $2.60 |
Technical Indicators
Market Signals| Indicator | PMCB | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 13.12 |
| Support Level | $0.33 | N/A |
| Resistance Level | $0.77 | $0.43 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 57.49 | 1.80 |
Price Performance
Historical ComparisonAbout PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.